ABAlicia Barreiro

Alicia Barreiro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alicia Barreiro has a total of 160 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Sutton’s naevi as a pitfall for reflectance confocal microscopy: marked inflamed naevi could not be suitable for teleconfocal examination

    by Albert Brugués, Simone Ribero, Alicia Barreiro, Sara Bassoli, Adriana P. García, Caterina Longo, Sonia Segura, Llúcia Alós, Josep Malvehy, Susana Puig, et al.

    Reflectance confocal microscopy (RCM) has been widely demonstrated to improve the noninvasive diagnostic accuracy of melanocytic tumors1. Some studies have focused on studying the use of teleconsultation of RCM images with experts as a promising opportunity for those doctors who have little experience in the field2. The clinical diagnosis of Sutton’s naevus is usually straightforward3: a melanocytic naevus surrounded by a symmetrical white circle4; however, sometimes inflammation makes identifying this entity challenging, as it can present atypical clinical and dermoscopic features. This atypical presentation of Sutton’s naevi can pose a diagnostic challenge. In addition, some groups, including ours, have recently published the confocal findings of such equivocal Sutton’s naevi5,6.


  • Differences in cutaneous melanoma survival between the 7th and 8th edition of the American Joint Committee on Cancer (AJCC). A multicentric population-based study

    by Alicia Barreiro-Capurro, Juan J. Andrés-Lencina, Sebastian Podlipnik, Cristina Carrera, Celia Requena, Esperanza Manrique-Silva, Pietro Quaglino, Luca Tonella, Ane Jaka, Nina Richarz, et al.


  • Melanocortin‐1 receptor (MC1R) genotypes do not correlate with size in two cohorts of medium‐to‐giant congenital melanocytic nevi

    by Neus Calbet‐Llopart, Mirella Pascini‐Garrigos, Gemma Tell‐Martí, Miriam Potrony, Vanessa Martins da Silva, Alicia Barreiro, Susana Puig, Guillaume Captier, Isabelle James, Nathalie Degardin, et al.

    Congenital melanocytic nevi (CMN) are cutaneous malformations whose prevalence is inversely correlated with projected adult size. CMN are caused by somatic mutations, but epidemiological studies suggest that germline genetic factors may influence CMN development. In CMN patients from the U.K., genetic variants in MC1R, such as p.V92M and loss‐of‐function variants, have been previously associated with larger CMN. We analyzed the association of MC1R variants with CMN characteristics in two distinct cohorts of medium‐to‐giant CMN patients from Spain (N = 113) and from France, Norway, Canada, and the United States (N = 53), similar at the clinical and phenotypical level except for the number of nevi per patient. We found that the p.V92M or loss‐of‐function MC1R variants either alone or in combination did not correlate with CMN size, in contrast to the U.K. CMN patients. An additional case–control analysis with 259 unaffected Spanish individuals showed a higher frequency of MC1R compound heterozygous or homozygous variant genotypes in Spanish CMN patients compared to the control population (15.9% vs. 9.3%; p = .075). Altogether, this study suggests that MC1R variants are not associated with CMN size in these non‐UK cohorts. Additional studies are required to define the potential role of MC1R as a risk factor in CMN development.


  • Open Access

    Melanocortin-1 receptor ( MC1R ) genotypes do not correlate with size in two cohorts of medium-to-giant congenital melanocytic nevi

    by Neus Calbet-Llopart, Mirella Pascini-Garrigos, Gemma Tell-Martí, Miriam Potrony, Vanessa Martins da Silva, Alicia Barreiro, Susana Puig, Guillaume Captier, Isabelle James, Nathalie Degardin, et al.

    Congenital melanocytic nevi (CMN) are cutaneous malformations whose prevalence is inversely correlated with projected adult size. CMN are caused by somatic mutations, but epidemiological studies suggest that germline genetic factors may influence CMN development. In CMN patients from the U.K., genetic variants in the MC1R gene, such as p.V92M and loss-of-function variants, have been previously associated with larger CMN. We analyzed the association of MC1R variants with CMN characteristics in 113 medium-to-giant CMN patients from Spain and from a distinct cohort of 53 patients from France, Norway, Canada and the U.S. These cohorts were similar at the clinical and phenotypical level, except for the number of nevi per patient. We found that the p.V92M or loss-of-function MC1R variants either alone or in combination did not correlate with CMN size, in contrast to the U.K. CMN patients. An additional case-control analysis with 259 unaffected Spanish individuals, showed a higher frequency of MC1R compound heterozygous or homozygous variant genotypes in Spanish CMN patients compared to the control population (15.9% vs. 9.3%; P =0.075). Altogether, this study suggests that MC1R variants are not associated with CMN size in these non-U.K. cohorts. Additional studies are required to define the potential role of MC1R as a risk factor in CMN development. SIGNIFICANCE: Congenital melanocytic nevi (CMN) are common pigmented lesions that originate during prenatal life, without clear evidence of a genetic predisposition. To date, limited data exist regarding the role of the MC1R gene, a key regulator of human pigmentation, in the development of the class of rarer CMN that are greater than 10 cm diameter at projected adult size and associated with increased morbidity or mortality risks. This study provides data from a large set of such CMN patients to support the hypothesis that MC1R could be involved in the development of these types of lesions, but at the same time discounting its influence on the size of CMN across distinct populations. Improving our understanding of genetic susceptibility to rare types of CMN is necessary to determine whether routine germline genotyping is relevant in clinical practice.

  • Factors associated with sentinel lymph node status and prognostic role of completion lymph node dissection for thick melanoma

    by Aram Boada, Antonio Tejera-Vaquerizo, Simone Ribero, Susana Puig, David Moreno-Ramírez, Pietro Quaglino, Simona Osella-Abate, Paola Cassoni, Josep Malvehy, Cristina Carrera, et al.


  • Diagnostic accuracy of imaging studies for initial staging of T2b to T4b melanoma patients: A cross-sectional study

    by Constanza Riquelme-Mc Loughlin, Sebastian Podlipnik, Xavier Bosch-Amate, José Riera-Monroig, Alicia Barreiro, Natalia Espinosa, David Moreno-Ramírez, Priscila Giavedoni, Ramon Vilana, Marcelo Sánchez, et al.


  • Open Access

    Clinical and Dermoscopic Evaluation of Melanocytic Lesions in Patients with Chronic Graft Versus Host Disease

    by A Barreiro-Capurro, J Mascaró, B Galindo, P Giavedoni, C Carrera, L Alos, S Puig, J Malvehy

    Patients treated with haematopoietic stem cell transplantation are at increased risk of cutaneous ma...


  • Improvement of diagnostic confidence and management of equivocal skin lesions by integration of reflectance confocal microscopy in daily practice: Prospective study in 2 referral skin cancer centers

    by Oriol Yélamos, Elena Manubens, Manu Jain, Marion Chavez-Bourgeois, Sri V. Pulijal, Stephen W. Dusza, Michael A. Marchetti, Alicia Barreiro, Maria L. Marino, Josep Malvehy, et al.


  • Detection of cell‐free circulating BRAF V 600E by droplet digital polymerase chain reaction in patients with and without melanoma under dermatological surveillance

    by N. Calbet‐Llopart, M. Potrony, G. Tell‐Martí, C. Carrera, A. Barreiro, P. Aguilera, S. Podlipnik, S. Puig, J. Malvehy, J. A. Puig‐Butillé

    Background The p.V600E mutation in the BRAF gene (BRAFV600E) is the most frequent mutation in cutaneous melanoma and is a recurrent alteration found in common benign naevi. The analysis of cell‐free BRAFV600E mutation (cfBRAFV600E) in plasma has emerged as a biomarker for monitoring prognosis and treatment response in melanoma patients. Objectives To quantify cfBRAFV600E levels in plasma from melanoma patients and from patients without melanoma having regular follow‐up of their melanocytic lesions, in order to assess the clinical significance of the test. Methods We quantified cfBRAFV600E by droplet digital PCR in plasma from 146 patients without melanoma undergoing continuous dermatological screening, 26 stage III and 7 stage IV patients with BRAF‐mutant melanoma, and 32 melanoma patients free of disease for 3 or more years. Results Among disease‐free patients and non‐melanoma individuals, 52% presented a high naevus count (>50) and 49% had clinically atypical naevi. cfBRAFV600E was detected in 71·4% of stage IV and 15·4% of stage III melanoma patients and in 1·4% of non‐melanoma individuals. No cfBRAFV600E was detected in disease‐free melanoma patients. Non‐melanoma individuals had lower cfBRAFV600E levels compared to melanoma patients. We established a variant allelic frequency of 0·26% or five cfBRAFV600E copies/mL as the optimal cut‐off value for identifying melanoma patients with >99% of specificity. Conclusions The study suggests that naevus related factors do not influence the detection of cfBRAFV600E in non‐melanoma individuals, and support the clinical diagnostic value of plasma cfBRAFV600E quantification in melanoma patients.


  • Open Access

    Inherited MC 1R variants in patients with melanoma are associated with better survival in women

    by F.E. Lira, S. Podlipnik, M. Potrony, G. Tell‐Martí, N. Calbet‐Llopart, A. Barreiro, C. Carrera, J. Malvehy, S. Puig

    Background Females have a better melanoma prognosis and fairer skin and hair colour. The presence of inherited MC1R variants has been associated with a better melanoma prognosis, but its interaction with sex is unknown. Objectives To evaluate the relationship between germline MC1R status and survival and determine any association with gender. Methods Cohort study including 1,341 melanoma patients from the Melanoma Unit of the Hospital Clínic of Barcelona, between January 1996 and April 2018. We examined known sex‐related prognosis factors as they relate to melanoma features and evaluated the sex‐specific role of the MC1R gene in overall survival and melanoma‐specific survival. Hazard ratios (HR) were calculated using univariate and multivariate Cox logistic regression. Results Males showed lower overall survival than females (P<.001) and the presence of inherited MC1R variants was not associated with better survival in our cohort. However, in the subgroup of female patients the presence of MC1R variants was associated with better overall survival in the multivariate analysis (HR 0.57; 95% CI 0.38‐0.85; P=.006), but not in male patients (HR 1.26; 95% CI 0.89‐1.79; P=.185) (P‐value for interaction P=.004). Analysis performed for melanoma‐specific survival showed the same level of significance. Limitations This was a single‐centre retrospective study. Conclusions Inherited MC1R variants is associated with improved overall survival in women with melanoma but not in men. Intrinsic sex‐dependent features can modify the role of specific genes in melanoma prognosis. We believe, therefore, that survival studies of melanoma patients should include analysis by sex and MC1R genotype.